Research - malecare.org

Salvage Therapy with High Dose Bicalutamide (Casodex) In Non-metastatic Castration-Resistant Prostate Cancer – It Controls PSA and Disease Progression

Researchers at the Department of Urology, Centre Hospitalier Universitaire du Québec (CHUQ), Quebec, Canada evaluated the rate and duration of prostate-specific antigen (PSA) response to high-dose bicalutamide (150 mg) in men with non-metastatic castration-resistant prostate cancer (nmHRPC) as well as its impact on the duration of metastasis-free survival. They concluded that high dose bicalutamide is [...]

By Malecare|2017-10-19T10:54:05-04:00April 12th, 2010|Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, Metastases, On The Horizon, Research, Uncategorized, Understanding APC|0 Comments

We Need Your Help Now

Currently, there is “Dear Colleague Letter” being circulated by two members of the U.S. House of Representatives, Jim Marshall (GA) and Peter King (NY) asking for support for increased funding for the Prostate Cancer Research Program (PCRP) — part of the Congressionally Directed Medical Research Program at the Department of Defense. The letters are circulated [...]

By Malecare|2021-02-17T10:57:32-05:00March 2nd, 2010|Advanced Prostate Cancer, Advocacy, General Information, Research, Uncategorized|0 Comments

Docetaxel-Based Chemotherapy with Zoledronic Acid and Prednisone in Hormone Refractory Prostate Cancer: Factors Predicting Response and Survival

We know that docetaxel chemotherapy (chemo) extends life, but which men might hope to experience an increase in survival? The Department of Urology, All India Institute of Medical Sciences, New Delhi, India performed a small study designed to evaluate the efficacy of docetaxel/prednisone and zoledronic acid in the treatment of men with hormone refractory prostate [...]

By Malecare|2017-10-19T10:54:14-04:00December 2nd, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Research, Uncategorized, Understanding APC|1 Comment

On the Horizon – A Quick Summary of the Status of Some of the Up Coming Treatments for Advanced Prostate Cancer

Provenge, a cancer vaccine, has demonstrated its ability to improve the survival of men with castrate resistant prostate cancer (CRPC). The developer, Dendreon, has submitted it latest clinical trial data to the FDA for approval. We hope to have an approval by mid-year 2010. Growth factors were thought to be potential targets for treating prostate [...]

By Malecare|2009-11-11T19:47:06-05:00November 11th, 2009|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, On The Horizon, Research, Uncategorized, vaccines|0 Comments

Late Stage Clinical Trials

I compiled a list of trials that are activily recruiting men with hormone refractory prostate cancer (HRPC) who have also failed chemotherapy (taxotere). Being at this point in the disease process is by far the scariest time. We face the reality that there are no more approved treatments available to control the cancer. Clinical trials [...]

By Malecare|2020-02-04T11:06:15-05:00October 19th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, End-Of-Life, How We Live, On The Horizon, Research, Uncategorized|0 Comments